BofA Analysts Say Novartis Has Levers to Offset Patent Cliff

Bank of America analysts say Novartis faces a patent cliff in the early 2030s, when three major drugs are due to lose exclusivity. Recent trial setbacks have affected prospects for upcoming patent expirations.